A new PEG-β-alanine active derivative for releasable protein conjugation

Bioconjugate Chemistry

Volumn 19, Issue 12, 2008, Pages 2427-2431

  Pasut, Gianfranco ^a   Mero, Anna ^a   Caboi, Francesca ^b   Scaramuzza, Silvia ^b   Sollai, Luigi ^b   Veronese, Francesco M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Bio Ker srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BLOOD; CARBOXYLATION; ISOMERS; RATS;

CONVENIENT PROPERTIES; GRANULOCYTE-COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; POLYMER CHAINS; PROTEIN CONJUGATES; PROTEIN CONJUGATIONS; PROTEIN MODIFICATIONS; SLOW RELEASE; THERAPEUTIC PROTEIN; Β-ALANINE;

PROTEINS;

BETA ALANINE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTIDINE; HUMAN GROWTH HORMONE; MACROGOL; PROTEIN PEG BETA ALANINE; TRIPTORELIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOEQUIVALENCE; CHEMICAL STRUCTURE; CONJUGATION; CONTROLLED STUDY; GROWTH HORMONE RELEASE; HALF LIFE TIME; HYPOPHYSECTOMY; MALE; NONHUMAN; PROTEIN MODIFICATION; PROTEIN SECRETION; RAT; RHESUS MONKEY; SPRAGUE DAWLEY RAT; WEIGHT GAIN;

RATTUS;

EID: 58149087871     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc800281s     Document Type: Article

References (15)

1. Lawrence, S. (2004) The biotech drug market. Nat. Biotechnol. 22, 1496.
2. Schellekens, H. (2005) Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 20, 3-9.
3. Veronese, F. M., and Pasut, G. (2005) PEGylation, successful approach to drug delivery. Drug Discovery Today 10, 1451-1457.
4. Veronese, F. M., and Harris, J. M. edrs. (2002) Theme issue on "Peptide and Protein Pegylation I". Adv. Drug Delivery Rev. 54, 453-606.
5. Pasut, G., and Veronese, F. M. (2007) Polymer-drug conjugation, recent achievements and general strategies. Prog. Polym. Sci. 32, 933-961.
6. Harris, J. M., and Chess, R. B. (2003) Effect of PEGylation on pharmaceuticals. Nature Rev. Drug. Discovery 2, 214-221.
7. Reddy, K. R., Modi, M. W., and Pedder, S. (2002) Use of peginterferon α2a (40KD) (Pegasys®) for the treatment of hepatitis C. Adv. Drug Delivery Rev. 54, 571-586.
8. Greenwald, R. B., Yang, K., Zhao, H., Conover, C. D., Lee, S., and Filpula, D. (2003) Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery system employing 1,6-elimination. Bioconjugate Chem. 14, 395-403.
9. Greenwald, R. B., Choe, Y. H., Conover, C. D., Shum, K., Wu, D., and Royzen, M. (2000) Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amino-containing compounds. J. Med. Chem. 43, 475-487.
10. Zhao, H., Yang, K., Martinez, A., Basu, A., Chintala, R., Liu, H. C., Janjua, A., Wang, M., and Filpula, D. (2006) Linear and branched bicin linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins. Bioconjugate Chem. 17, 341-351.
11. Peleg-Shulman, T., Tsubery, H., Mironchik, M., Fridkin, M., Schreiber, G., and Shechter, Y. (2004) Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. J. Med. Chem. 7, 4897-4904.
12. Pasut, G., Caboi, F., Schrepfer, R., Tonon, G., Schiavon, O., and Veronese, F. M. (2007) New active poly(ethylene glycol) derivative for amino coupling. React. Funct. Polym. 67, 529-539.
13. Pasut, G., Scaramuzza, S., Schiavon, O., Mendichi, R., and Veronese, F. M. (2005) PEG-epirubicin conjugates with high drug loading. J. Bioact. Compat. Polym. 20, 213-230.
14. Snyder, S. L., and Sobocinski, P. Z. (1975) An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines. Anal. Biochem. 64, 284-288.
15. Clark, R., Olson, K., Fuh, G., Mariani, M., Mortensen, D., and Teshima, G. (1996) Long-acting growth hormones produced by conjugation with polyethylene glycol. J. Biol. Chem. 271, 21969-21977.